We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Xilio Therapeutics Inc (XLO) USD0.0001

Sell:$0.78 Buy:$0.79 Change: $0.0545 (7.51%)
NASDAQ:1.22%
Market closed |  Prices as at close on 4 October 2024 | Switch to live prices |
Sell:$0.78
Buy:$0.79
Change: $0.0545 (7.51%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 4 October 2024 | Switch to live prices |
Sell:$0.78
Buy:$0.79
Change: $0.0545 (7.51%)
Market closed |  Prices as at close on 4 October 2024 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Xilio Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The Company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies (including bispecifics) and immune cell engagers (including tumor-activated cell engagers and tumor-activated effector-enhanced cell engagers). Its product pipeline includes XTX101, XTX301, XTX202, XTX501, and tumor-activated bispecific molecules and immune cell engager molecules. XTX101 is an investigational tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4 monoclonal antibody.

Contact details

Address:
828 Winter Street, Suite 300
WALTHAM
02451
United States
Telephone:
+1 (617) 4304680
Website:
https://xiliotx.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
XLO
ISIN:
US98422T1007
Market cap:
$33.31 million
Shares in issue:
43.95 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Rene Russo
    President, Chief Executive Officer, Director
  • Christopher Frankenfield
    Chief Operating Officer
  • Kevin Brennan
    Senior Vice President - Finance & Accounting
  • Scott Coleman
    Chief Development Officer
  • Katarina Luptakova
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.